Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Na ïve Advanced Pancreatic Neuroendocrine Tumors.

CONCLUSION: BEZ235 treatment in mTOR inhibitor-naïve patients with advanced pNET did not demonstrate increased efficacy compared with everolimus and may be associated with a poorer tolerability profile. PMID: 29242283 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29242283?dopt=Abstract

Source: The Oncologist - December 14, 2017 Category: Cancer & Oncology Authors: Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC Tags: Oncologist Source Type: research